Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
about
Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cellsBrachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancerRetroviral oncogenes: a historical primerTargeting the PI3K signaling pathway in cancerOvercoming resistance to targeted therapies in NSCLC: current approaches and clinical applicationNew and emerging factors in tumorigenesis: an overviewTransformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of originMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularLigand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligandsIrreversible EGFR-TKIs: dreaming perfectionIn vitro and in vivo models for analysis of resistance to anticancer molecular therapiesThe role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancerTargeted therapies in development for non-small cell lung cancerRole of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agentsMet receptor acts uniquely for survival and morphogenesis of EGFR-dependent normal mammary epithelial and cancer cellsCancer genome sequencing: understanding malignancy as a disease of the genome, its conformation, and its evolution.Molecular pathology of lung cancer: key to personalized medicine.Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsALK mutations conferring differential resistance to structurally diverse ALK inhibitors.Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-JunCurrent Therapeutic Advances Targeting EGFR and EGFRvIII in GlioblastomaPTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFRGenome stability pathways in head and neck cancersAntitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitorsA novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancersDifferences in the binding affinities of ErbB family: heterogeneity in the prediction of resistance mutantsIdentifying and quantifying heterogeneity in high content analysis: application of heterogeneity indices to drug discoveryMET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC CellsRegistered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulationsProfiling Y561-dependent and -independent substrates of CSF-1R in epithelial cellsAcquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3KHepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition.Four individually druggable MET hotspots mediate HGF-driven tumor progression.Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors.A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors.
P2860
Q24309725-13C56BC2-78BB-4652-ACDE-7764CC4B3046Q24324198-DF3514B9-723A-4A94-9401-19721F59D3ACQ24611142-2392A4E9-C5D4-4398-AC36-A6C6B147131FQ24647554-26DC8AE3-FAD9-47B7-89F0-80ECC97D75C4Q26795556-A951CDC0-49FC-48FC-AC90-A394D5CC32ABQ26801253-EC9D28C4-D408-4E83-96EC-7CF66F6CA396Q26826437-18310984-C7C7-4D90-AAE3-F2C1C178FA61Q26828860-BD9E7BFF-C635-4F10-B0CE-F5323EF9C183Q26829104-474B8105-75DA-4891-AB13-35F8F57A539AQ26866186-413C3BE8-0B4C-4DDC-A1A3-513DEEEB0F84Q27014174-6AC053F1-D9BA-4DC6-B719-134DF11DBB67Q27021738-A5E87E82-6C76-45AA-AC76-AB445E5307EEQ27022852-9769FFD8-7D02-4753-AE2A-D4BF2E18A0D4Q27027957-69109272-99C8-47C9-BEBB-A1B77F812A6FQ27318931-B8B798B8-3980-424C-A593-DEDDBBAB7060Q27690285-E06FB3D7-AAC3-4A64-ABDE-51664C686BC7Q27691299-09B7AE40-53A7-444A-BB3D-54BED1B5A8F0Q27851589-DFC30A4D-BF48-4B82-BF9E-9B49073F01E7Q27851628-7EDEC3E2-19D3-4D3B-8B21-D389BE805F32Q27851633-6D397959-293B-4BB0-9A29-1DBCD7360BA2Q27851672-A0F9EC61-366B-4743-A153-5201A4D7C22AQ27851710-C4869383-5BF9-44AE-81DC-41EF36540E3BQ27851896-63EAEF20-AF4E-4C7C-AD06-37DA3BC16C2AQ27852235-77C01EC6-E979-42C2-BFD0-A64F00CDC22DQ27853317-3A862502-A60A-4D2F-BB28-9D0ECA32D209Q28087306-E7FC4989-58CF-41AE-83DC-C4D9C6B1AD1FQ28240702-3B846B9F-237D-48CF-8CE5-4F1E0BE61B7BQ28391355-8CA04CEB-D818-484D-9355-2846338F8C75Q28478344-746C55AF-26B1-4F60-AAC4-A1DD59D0F2B8Q28485310-407D11C4-2404-42BB-B38A-6F3B37F311C5Q28534601-E71CAD69-43D0-41F7-97D0-CF138893B48BQ28540918-3C00C032-4B45-450B-93A1-DEA7699CD0A6Q28551045-B3779D38-B948-4251-A5D0-281EE7F96426Q28603408-A522D37D-E01B-4C5F-8AFE-C46F51B989FEQ28748716-C4CA1EC9-E19B-482D-BD3E-E563F8954284Q29614757-856AFAA4-401F-42B4-A0A8-1EE19DCC19FFQ30414265-21AE4044-0F1C-48F3-BD17-964560F62B4DQ30581656-2AFDF172-657F-423E-81A7-08E50C4319E4Q33396953-7E440867-6E46-4FC3-BB84-AC095934DE83Q33556988-DD0D9B16-32CB-49A0-B6FA-FCB26DFF01AA
P2860
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Mechanisms of acquired resista ...... in non-small cell lung cancer.
@ast
Mechanisms of acquired resista ...... in non-small cell lung cancer.
@en
Mechanisms of acquired resista ...... in non-small cell lung cancer.
@nl
type
label
Mechanisms of acquired resista ...... in non-small cell lung cancer.
@ast
Mechanisms of acquired resista ...... in non-small cell lung cancer.
@en
Mechanisms of acquired resista ...... in non-small cell lung cancer.
@nl
prefLabel
Mechanisms of acquired resista ...... in non-small cell lung cancer.
@ast
Mechanisms of acquired resista ...... in non-small cell lung cancer.
@en
Mechanisms of acquired resista ...... in non-small cell lung cancer.
@nl
P1476
Mechanisms of acquired resista ...... in non-small cell lung cancer.
@en
P2093
Jeffrey A Engelman
P304
P356
10.1158/1078-0432.CCR-07-2248
P407
P50
P577
2008-05-01T00:00:00Z